Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled lot consistency study of V181 tetravalent live-attenuated dengue vaccine in healthy adults
MOH_2024-01-15_013190Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2024
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of TetraVax-DV in dengue fever (4 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability and Lot-to-lot immunogenicity consistency. Started Mar 2024; status: completed.
02
Drugs
TetraVax-DV
03
Conditions
dengue fever
Beyond the preview
Go deeper on MOH_2024-01-15_013190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-15_013190.